Stocks Health care ANIK
NASDAQ · Health careAnika Therapeutics, Inc. (ANIK)
Anika Therapeutics, Inc. brought in $120.7M of revenue over the twelve months to June 30, 2026, up 5.3% from a year earlier. It posted a net loss of $3.8M. Operating cash flow minus capital spending left $4.4M of free cash flow in fiscal 2025. At June 30, 2026 it held $38.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 29, 2026.
What Anika Therapeutics, Inc. does
Anika Therapeutics, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker ANIK.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $112.8M | -$10.9M | -$0.76 | $4.4M |
| 2024 | $119.9M | -$56.4M | -$3.83 | -$2.3M |
| 2023 | $120.8M | -$82.7M | -$5.64 | -$7.2M |
| 2022 | $113.8M | -$14.9M | -$1.02 | -$3.1M |
| 2021 | $147.8M | $4.1M | $0.28 | $3.3M |
| 2020 | $130.5M | -$24M | -$1.69 | $11.4M |
Latest SEC filings
What Anika Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- July 31, 2026Passive stake changed SCHEDULE 13G/A
- July 29, 2026
- July 29, 2026Quarterly report 10-Q · period to June 30, 2026
- July 29, 2026
- July 17, 2026Passive stake changed SCHEDULE 13G/A
- July 14, 2026
- June 23, 2026
- June 8, 2026Additional proxy material DEFA14A
- June 1, 2026Additional proxy material DEFA14A
- April 30, 2026Quarterly report 10-Q · period to March 31, 2026
Questions about ANIK
What does Anika Therapeutics, Inc. do?
Anika Therapeutics, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker ANIK.
Is Anika Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $3.8M on revenue of $120.7M.
How much revenue does Anika Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Anika Therapeutics, Inc. reported revenue of $120.7M. That is 5.3% more than a year earlier.
When did Anika Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 29, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the planned insider sale from August 7, 2026.
Similar companies
Follow ANIK
Get an email when Anika Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow ANIK: get an email when it filesWhere the numbers come from
Financial figures are the values Anika Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.